Loading
The 2025 summary of the US NCCN guideline for gallbladder and bile duct cancers, focused on what to give after surgery.
Journal summary of the NCCN Guidelines for Biliary Tract Cancers, version 2.2025, which cover gallbladder cancer, intrahepatic and extrahepatic cholangiocarcinoma. The panel meets at least yearly to review requests and new data; this manuscript focuses on the adjuvant chemotherapy and chemoradiation recommendations. The 2023 Insights paper (Benson et al., JNCCN 2023, PMID 37433432) recorded the split of the former Hepatobiliary Cancers guideline into separate Hepatocellular Carcinoma and Biliary Tract Cancers guidelines.
NCCN is the source of the category grades quoted on the gallbladder cancer page; the adjuvant section leans on BILCAP for capecitabine and on SWOG S0809 for chemoradiation after margin-positive or node-positive resection.
Shares SWOG S0809, BILCAP, Gallbladder cancer and the tag gallbladder-evidence.
Shares SWOG S0809, Gallbladder cancer and the tag gallbladder-evidence.
Shares Biliary tract cancer (cholangiocarcinoma), Gallbladder cancer and the tag gallbladder-evidence.
Shares Biliary tract cancer (cholangiocarcinoma), Gallbladder cancer and the tag gallbladder-evidence.
Shares BILCAP, Gallbladder cancer and the tag gallbladder-evidence.
Shares SWOG S0809, Gallbladder cancer and the tag gallbladder-evidence.
Shares BILCAP, Gallbladder cancer and the tag gallbladder-evidence.
Shares Biliary tract cancer (cholangiocarcinoma), Gallbladder cancer and the tag gallbladder-evidence.